ReviewBreast cancer : basic and clinical research2020
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.
Review in Breast cancer : basic and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 4 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Exercise and pathologic complete response to cancer treatment: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Diagnostic accuracy of contrast-enhanced mammography in evaluating breast cancer response to neoadjuvant therapy: a systematic review and meta-analysis.La Radiologia medica · 2026Pooled it
- Guidelines for breast cancer management in Bosnia and Herzegovina.Biomolecules & biomedicine · 2023Guideline
- Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review.BMJ open · 2022Pooled it
- Effect of adding indocyanine green to identifying sentinel lymph node in breast cancer patients after neoadjuvant chemotherapy.Revista da Associacao Medica Brasileira (1992) · 2026Trial
- Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.Scientific reports · 2024Trial
- Early Prediction of the Breast Cancer Response to Neoadjuvant Chemotherapy Based on Intratumoral Interstitial Fluid Pressure using 3-D Subharmonic-Aided Pressure Estimation.Ultrasound in medicine & biology · 2026Article
- Review
- Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer.Current oncology (Toronto, Ont.) · 2026Review
- Changes in active DNA demethylation pathway components during neoadjuvant chemotherapy and their prognostic significance in breast cancer.Breast cancer research : BCR · 2026Article
- Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia.Current oncology (Toronto, Ont.) · 2026Article
- Residual disease after neoadjuvant therapy in HER2-positive breast cancer: biology, burden, or both?Translational cancer research · 2026Article
- Evaluating the Predictive Value of Post-Treatment Superb Microvascular Imaging for Complete Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.Bioengineering (Basel, Switzerland) · 2026Article
- Residual Primary Breast Cancer After Chemotherapy: Assessment of Recurrence and Survival.Cureus · 2026Article
- Unlocking synergistic potential: enhancing paclitaxel efficacy in combination with silibinin in breast cancer cell line through H19 LncRNA and P53/Bax/Bcl2 axis.Annals of medicine and surgery (2012) · 2026Article
- Time-Dependent DCE-MRI Radiomics to Predict Response to Neoadjuvant Therapy in Breast Cancer: A Multicenter Study with External Validation.Diagnostics (Basel, Switzerland) · 2026Article
- Deep learning-based radiomics does not improve residual cancer burden prediction post-chemotherapy in LIMA breast MRI trial.European radiology · 2026Article
- SanHuang decoction may suppress breast cancer by regulating M1 macrophage polarization via NF-κB signaling pathway:Translational cancer research · 2026Article
- Dual-input spatio-temporal transformer model: Predicting the efficacy of NACT in breast cancer based on DCE-MRI images.iScience · 2026Article
- Ensemble Machine Learning on Bulk RNA-Seq Identifies 17-Gene Signature Predicting Neoadjuvant Chemotherapy Response in Breast Cancer.Current issues in molecular biology · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Neoadjuvant chemotherapy (NAC) had been developed as a systematic approach before definitive surgery for the treatment of locally advanced or inoperable breast cancer such as inflammatory breast cancer in the past. In addition to its impact on surgery, the neoadjuvant setting has a benefit of providing the opportunity to monitor the individual drug response. Currently, the subject of NAC has expanded to include patients with early-stage, operable breast cancer because it is revealed that the achievement of a pathologic complete response (pCR) is associated with excellent long-term outcomes, especially in patients with aggressive phenotype breast cancer. In addition, this approach provides the unique opportunity to escalate adjuvant therapy in those with residual disease after NAC. Neoadjuvant chemotherapy in breast cancer is a rapidly evolving topic with tremendous interest in ongoing clinical trials. Here, we review the improvements and further challenges in the NAC setting in translational breast cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.